다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
ImmunoPrecise Antibodies Ltd (IPA)
ImmunoPrecise Antibodies Ltd (IPA) 뉴스

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IPA

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/13	02:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/12	20:00	Business Wire	BioStrand, filiale d’ImmunoPrecise Antibodies Ltd., reçoit le prestigieux prix Impact 2024 pour sa technologie LENSai™ révolutionnaire	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/12	20:00	Business Wire	ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/11	03:23	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/11	00:34	Business Wire	BioStrand, filiale d’ImmunoPrecise Antibodies, annonce la disponibilité commerciale immédiate de son logiciel révolutionnaire doté d’une interface personnalisable pour la découverte de médicaments optimisée par l’IA	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/10	20:15	Business Wire	BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/05	06:01	Business Wire	La filiale d’IPA, BioStrand, annonce un LLM avancé pour les dossiers de santé électroniques	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/05	05:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/06/04	20:00	Business Wire	IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/29	03:35	Business Wire	InterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IA	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/28	20:02	Business Wire	InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/21	02:52	Business Wire	IPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IA	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/20	20:02	Business Wire	IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/15	08:39	Business Wire	IPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/14	21:05	Business Wire	IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/08	05:24	Business Wire	BioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFT	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/08	01:19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/07	21:02	Business Wire	IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/05	06:50	Business Wire	L'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/03/04	22:01	Business Wire	IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/02/24	07:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/02/24	07:26	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/02/16	05:12	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/01/11	03:53	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2024/01/11	03:33	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2023/12/15	05:08	Business Wire	IPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024*	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2023/12/14	22:48	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2023/12/14	22:38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2023/12/14	22:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd
2023/12/14	22:01	Business Wire	IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*	NASDAQ:IPA	ImmunoPrecise Antibodies Ltd

검색 관련기사 보기:NASDAQ:IPA

1 2 3 4 5 6 7 8 다음 >>

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관